Merck & Co., Inc.
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Lagevrio (molnupiravir by Year
Lagevrio (molnupiravir — COVID-19 oral antiviral, Ridgeback alliance) — U.S. sales ($M) ($M)
Merck Lagevrio (molnupiravir: $101M in FY2025, down 42.6% from a year earlier.
Where the FY2025 figure comes from
“|| Lagevrio | 380 | 964 | -61 | 101 | 176 | -43 | 278 | 787 | -65”
Source: Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Lagevrio (molnupiravir — COVID-19 oral antiviral, Ridgeback alliance) — U.S. sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 101 | -42.6% | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 176 | +1,660.0% | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2023 | Dec 31, 2023 | 10 | -99.3% | Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗ |
| FY2022 | Dec 31, 2022 | 1,523 | +141.0% | Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗ |
| FY2021 | Dec 31, 2021 | 632 | – | Form 10-K (filed 2024-02-26) ↗ |
| FY2020 | Dec 31, 2020 | 0 | – | Form 10-K (filed 2023-02-24) ↗ |
| FY2019 | Dec 31, 2019 | 0 | – | Form 10-K (filed 2022-02-25) ↗ |
Cite this data
StockData. (2026). Merck Lagevrio (molnupiravir ($M), annual FY2019–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-lagevrio-us
See every metric in the Merck KPI table. Data updated Oct 26, 2026.